NTRK1 and neoplasm: Herein, we propose a new layer of complexity in which mutations affecting genes involved in different pathways (e.g. pseudohypoxic and receptor tyrosine kinase signalling) (Supplementary Figure 3) co-occurring in the same patient, either in the germline or in the tumour, could provide a selective advantage for the development of PPGL.